Anaplastic Oligoastrocytoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Anaplastic Oligoastrocytoma – Pipeline Review, H2 2017’, provides an overview of the Anaplastic Oligoastrocytoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Oligoastrocytoma

The report reviews pipeline therapeutics for Anaplastic Oligoastrocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anaplastic Oligoastrocytoma therapeutics and enlists all their major and minor projects

The report assesses Anaplastic Oligoastrocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anaplastic Oligoastrocytoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anaplastic Oligoastrocytoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anaplastic Oligoastrocytoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Boehringer Ingelheim GmbH

Cavion LLC

Celldex Therapeutics Inc

Leadiant Biosciences Inc

Novartis AG

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Anaplastic Oligoastrocytoma - Overview 6

Anaplastic Oligoastrocytoma - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Anaplastic Oligoastrocytoma - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development 20

AbbVie Inc 20

Boehringer Ingelheim GmbH 20

Cavion LLC 21

Celldex Therapeutics Inc 21

Leadiant Biosciences Inc 21

Novartis AG 22

Pfizer Inc 22

Anaplastic Oligoastrocytoma - Drug Profiles 24

afatinib dimaleate - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

CDX-1401 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Cellular Immunotherapy for Gliomas - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

depatuxizumab mafodotin - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

flucytosine + TBio-01 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

irinotecan hydrochloride + TBio-02 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

mibefradil dihydrochloride - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

nilotinib - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

palbociclib - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

procarbazine hydrochloride - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

TBX.OncV NSC - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Anaplastic Oligoastrocytoma - Dormant Projects 74

Anaplastic Oligoastrocytoma - Discontinued Products 75

Appendix 76

Methodology 76

Coverage 76

Secondary Research 76

Primary Research 76

Expert Panel Validation 76

Contact Us 76

Disclaimer 77

List of Tables

List of Tables

Number of Products under Development for Anaplastic Oligoastrocytoma, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Anaplastic Oligoastrocytoma – Pipeline by AbbVie Inc, H2 2017 20

Anaplastic Oligoastrocytoma – Pipeline by Boehringer Ingelheim GmbH, H2 2017 20

Anaplastic Oligoastrocytoma – Pipeline by Cavion LLC, H2 2017 21

Anaplastic Oligoastrocytoma – Pipeline by Celldex Therapeutics Inc, H2 2017 21

Anaplastic Oligoastrocytoma – Pipeline by Leadiant Biosciences Inc, H2 2017 22

Anaplastic Oligoastrocytoma – Pipeline by Novartis AG, H2 2017 22

Anaplastic Oligoastrocytoma – Pipeline by Pfizer Inc, H2 2017 23

Anaplastic Oligoastrocytoma – Dormant Projects, H2 2017 74

Anaplastic Oligoastrocytoma – Discontinued Products, H2 2017 75

List of Figures

List of Figures

Number of Products under Development for Anaplastic Oligoastrocytoma, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Top 10 Targets, H2 2017 12

Number of Products by Stage and Top 10 Targets, H2 2017 12

Number of Products by Top 10 Mechanism of Actions, H2 2017 14

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports